The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Groups Develop Request for Proposals for Research Grants Focused on Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations This collaboration seeks to address important mechanistic ...